ARCHIVES

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

This article is from The Cancer Letter archive.

Vol. 30 No. 31 | July 30, 2004

Download PDF Visit The Full Archive

Related Articles

IVAX And It’s Portfolio

December 22, 1994

AOR And PRN, Two Largest Oncology Practice Management Firms, To Merge

December 18, 1998

President Proposes $1 Billion Increase For NIH In FY2011; Cancer A High Priority

February 5, 2010

DCBD Board Approves Concepts For 43.5 Million In New Grants, $1.9 Million In Contract Supported Projects

November 13, 1981

In brief: ring appointed Associate Dean At UCSF; Univ. of Utah Forms Cell Signaling Center

August 1, 1997

DCT To Announce June 1 Guidelines For CREG Program In Cell Kinetics Related To Chemo, Radiotherapy

April 25, 1975